DE-111 Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular Hypertension

Phase 3 Completed 148 enrolled Santen Pharmaceutical Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

Safety and IOP (intraocular pressure) lowering effect of DE-111 ophthalmic solution will be evaluated in open-angle glaucoma or ocular hypertension patients, in an open-label, multicenter study.

Timeline

Start: 2011-05
Primary completion: 2013-03
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	DE-111	Unknown	—	Other

DE-111 Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular Hypertension

Summary

Timeline

Drugs

Indications